Navigation Links
AEterna Zentaris: Lead Investigator for Cetrorelix Trials in BPH Wins Best Poster Presentation Award at European Association of Urology Meeting in Milan
Date:4/30/2008

QUEBEC CITY, April 30 /PRNewswire-FirstCall/ - AEterna Zentaris Inc. (NASDAQ: AEZS, TSX: AEZ), a global biopharmaceutical company focused on endocrine therapy and oncology, today announced that Prof. Frans M.J. Debruyne, M.D., Ph.D., Chairman and CEO of Andros Men's Health Institutes in The Netherlands, won the award for Best Poster Presentation in a Poster Session at the 23rd Annual European Association of Urology Meeting, which was held March 26-28, 2008 in Milan, Italy. Titled "LHRH antagonist cetrorelix for symptomatic BPH: Prolonged improvement beyond end of treatment in placebo-controlled trials." FMJ Debruyne, A.A. Gres, A. Bantschev, M. Tzvetkov, K. Grdovic, the poster referred to previously disclosed results from two Phase 2 trials with cetrorelix in benign prostatic hyperplasia (BPH), which showed a prolonged duration of effect extending far beyond the end of the short-term treatment course.

Prof. Jurgen Engel, Ph. D., Executive Vice President, Scientific Affairs at AEterna Zentaris commented, "We would like to congratulate Professor Debruyne for this prestigious award which acknowledges his significant contribution to the quality and achievements of our drug development program with cetrorelix in BPH. The data observed in these Phase 2 trials warranted our current extensive Phase 3 program with cetrorelix in this same indication and we look forward to presenting the results in Q3 2009, as stated previously. We believe cetrorelix could provide a novel, efficient, convenient and safe treatment for the millions of men with BPH."

THE POSTER

Introduction and Objectives

Preliminary studies indicated prolonged, unmaintained improvement in signs and symptoms of BPH after short courses of cetrorelix. Tw
'/>"/>

SOURCE AETERNA ZENTARIS INC.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. AEterna Zentaris Partner, Spectrum, Provides Update on Ozarelix in Benign Prostatic Hyperplasia
2. AEterna Zentaris Completes Patient Recruitment for First Phase 3 Efficacy Trial with Cetrorelix in Benign Prostatic Hyperplasia
3. AEterna Zentaris Announces Changes to its Management Team
4. AEterna Zentaris and Paladin Labs Complete Sale and Purchase of Miltefosine Rights
5. Aeterna Zentaris Begins Second Phase 3 Trial of Cetrorelix for Benign Prostatic Hyperplasia
6. Aeterna Zentaris Reports Fourth Quarter and Full-Year 2007 Financial and Operating Results
7. AEterna Zentaris and Paladin Labs Announce Sale and Purchase of Miltefosine Rights
8. AEterna Zentaris Announces the Departure of SVP, Administrative and Legal Affairs
9. Aeterna Zentaris to Announce Fourth Quarter and Full-Year 2007 Financial and Operating Results on March 5, 2008
10. AEterna Zentaris to Present at the Upcoming Roth Capital Partners 20th Annual OC Growth Stock Conference in Dana Point, California
11. AEterna Zentaris Reports First Patients Treated with Anti-Cancer Compound AEZS-108 in Phase 2 Trial in Ovarian and Endometrial Cancers
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/29/2014)... Research and Markets  has announced the addition of ... Chromatograph Market by Type , Technology, Spectroscopy, Gas chromatography, ... to 2013 - 2020" report to their offering. ... analytical instrument that provides chemical composition data on process ... which companies carry out their production and improve the ...
(Date:9/29/2014)... , Sept. 29, 2014  Atlas Venture, an ... sciences and technology innovation, today announced that Jason ... (NASDAQ: EPZM ), is joining the firm,s ... 1, 2014. At Atlas, Rhodes will work ... companies. He brings an accomplished record in company creation, ...
(Date:9/29/2014)... , September 29, 2014 ... greater competition to transform network connectivity as customers ... ProLabs , the leading independent ... today the findings of their survey conducted at ... with top optical communications professionals from across the ...
(Date:9/29/2014)... 29, 2014 CytRx Corporation (NASDAQ: ... company specializing in oncology, today announced that the ... multiple Orphan Drug Designations for the Company,s lead ... (GBM), small cell lung cancer and ovarian cancer.  ... chemotherapeutic agent, doxorubicin. "The FDA,s decision ...
Breaking Biology Technology:Global Process Liquid Analyzer, Gas Analyzer, and Gas Chromatograph (PH/ORP, Chlorine, Oxygen, Carbon dioxide) Market - Trends & Forecast to 2020 2Global Process Liquid Analyzer, Gas Analyzer, and Gas Chromatograph (PH/ORP, Chlorine, Oxygen, Carbon dioxide) Market - Trends & Forecast to 2020 3Global Process Liquid Analyzer, Gas Analyzer, and Gas Chromatograph (PH/ORP, Chlorine, Oxygen, Carbon dioxide) Market - Trends & Forecast to 2020 4Atlas Venture Names Jason Rhodes, Veteran Investor and President and CFO of Epizyme, As Partner on Life Sciences Investing Team 2End of an Era: OEM Dominance - Could it be a Thing of the Past? 2CytRx Receives Multiple FDA Orphan Drug Designations for Aldoxorubicin for the Treatment of Glioblastoma, Small Cell Lung Cancer and Ovarian Cancer 2CytRx Receives Multiple FDA Orphan Drug Designations for Aldoxorubicin for the Treatment of Glioblastoma, Small Cell Lung Cancer and Ovarian Cancer 3CytRx Receives Multiple FDA Orphan Drug Designations for Aldoxorubicin for the Treatment of Glioblastoma, Small Cell Lung Cancer and Ovarian Cancer 4CytRx Receives Multiple FDA Orphan Drug Designations for Aldoxorubicin for the Treatment of Glioblastoma, Small Cell Lung Cancer and Ovarian Cancer 5
... ... due to personal emergency situations when parents leave behind their children at ... but a recent case revealed that at least one couple left behind ... If you suspect abandonned children might be siblings, how can you find ...
... , , , , BOTHELL, Wash., Dec. 23 BioLife ... and marketer of biopreservation tools for cells, tissues, and organs, ... quality systems and GMP production facility in Bothell, Washington by ... 13485:2003, an international standard for quality systems supporting the design, ...
... , , , , SHANGHAI, ... ), a,leading pharmaceutical, biotechnology, and medical-device research and,development outsourcing company ... winners of its third Life Science and Chemistry Awards,held on ... , (Logo: http://www.newscom.com/cgi-bin/prnh/20040705/CNM002LOGO ) ...
Cached Biology Technology:Paternity Testing Without Father and Mother? The German Company bj-diagnostik Investigates that Two babies Separately Left at Charity Institution are Siblings 2Paternity Testing Without Father and Mother? The German Company bj-diagnostik Investigates that Two babies Separately Left at Charity Institution are Siblings 3BioLife Solutions Achieves ISO 13485 Quality Management Systems Certification 2BioLife Solutions Achieves ISO 13485 Quality Management Systems Certification 3WuXi PharmaTech (NYSE: WX) Holds Its Third Life Science and Chemistry Awards Ceremony in Beijing 2WuXi PharmaTech (NYSE: WX) Holds Its Third Life Science and Chemistry Awards Ceremony in Beijing 3WuXi PharmaTech (NYSE: WX) Holds Its Third Life Science and Chemistry Awards Ceremony in Beijing 4
(Date:9/29/2014)... dinosaurs, gigantic reptilesdistant relatives of modern crocodilesruled the earth. ... it was thought they didn,t much interact. But a ... in the thigh of one of these ancient animals ... earth and planetary sciences lecturer, and her Virginia Tech ... marks in the thigh bones of an old reptile ...
(Date:9/29/2014)... not normally considered capable of doing anything on their ... move through water. In the future, such moving droplets ... your own to be self-moving is a ... entities can be self-moving, report researchers from University of ... Czech Republic. , The researchers have made alcohol droplets ...
(Date:9/29/2014)... A new model developed by researchers at the University ... the massive ice sheet covering most of Greenland is ... suggested, which would accelerate the rising sea levels that ... the impact of the increasing levels of meltwater created ... climate continues to warm, the new model also takes ...
Breaking Biology News(10 mins):Tooth serves as evidence of 220 million-year-old attack 2Scientists make droplets move on their own 2Greenland Ice Sheet more vulnerable to climate change than previously thought 2Greenland Ice Sheet more vulnerable to climate change than previously thought 3
... first time, researchers have developed a way to synthesize a ... it works. , Derived from a fungus discovered clinging to ... certain cancer cells into suicide while leaving healthy cells untouched. ... might have some tremendous potential as a prototype anticancer agent, ...
... cell count" burst into the world's medical vocabulary as ... The public began to understand the crucial importance of ... infection and guarding against future attacks. , While scientists ... diseases, one area has remained murky: disorders caused by ...
... together, and most people find it impossible to tell ... just about everything, including their genes. But sometimes only ... both of them should. , Scientists at the University ... how two people who are so similar biologically can ...
Cached Biology News:New lab technique churns out fungus' potential cancer fighter 2Researchers add crucial information on how the body's T cells react to parasitic diseases 2Researchers add crucial information on how the body's T cells react to parasitic diseases 3How can identical twins be genetically different? 2How can identical twins be genetically different? 3
... laser scanners is the starting point of ... ,Gene expression analysis, SNP (Single Nucleotide Polymorphism) ... the advancement of research in the post-genomics ... formats and sizes. These arrays call for ...
... provides the sensitivity and versatility you expect ... photon counting with selected photomultipliers ensure superior ... Equipped with up to 2 reagent injectors ... gene assays as well as other luminescence ...
...
Cell Culture Flask, 25 cm, tissue-culture treated polystyrene...
Biology Products: